Why was MK-677 placed on the FDA Category 2 list?

MK-677 (ibutamoren) was placed on the FDA Category 2 list due to safety concerns including potential for congestive heart failure, insulin resistance, and the absence of large-scale human safety data from FDA-supervised trials. Despite being the most studied GH secretagogue, its long-term safety profile in the general population has not been established through the regulatory approval process.

GH & Body Composition

GH Secretagogues vs HGH for Body Composition

14 min read|March 21, 2026

GH & Body Composition

~3 kg fat-free mass gain

MK-677, an oral growth hormone secretagogue, increased fat-free mass by approximately 3 kg in obese subjects over eight weeks in a randomized, placebo-controlled trial.

Svensson et al., Journal of Clinical Endocrinology & Metabolism, 1998

View as image

Growth hormone secretagogues (GHS) and exogenous human growth hormone (HGH) both increase circulating GH levels, but they do so through fundamentally different mechanisms that produce different physiological outcomes. HGH delivers a fixed dose of recombinant growth hormone directly into the bloodstream, bypassing the hypothalamic-pituitary axis entirely. GHS compounds like GHRP-2, GHRP-6, ipamorelin, sermorelin, and MK-677 (ibutamoren) stimulate the pituitary to release its own GH, preserving the pulsatile secretion pattern that characterizes natural GH physiology.^[1] This difference has consequences for body composition outcomes, side effect profiles, and regulatory status. For the broader relationship between growth hormone and body fat, see our pillar article on visceral fat and growth hormone.

Key Takeaways

MK-677 increased fat-free mass by approximately 3 kg over eight weeks in obese subjects while raising 24-hour GH secretion 1.8-fold compared to placebo (Svensson et al., 1998)
Ipamorelin is the only GH secretagogue that stimulates GH release without simultaneously increasing ACTH, cortisol, or prolactin, giving it the cleanest hormonal profile in the class (Raun et al., 1998)
GHS preserve pulsatile GH secretion patterns, while exogenous HGH creates sustained supraphysiological levels that suppress endogenous production through negative feedback
Exogenous HGH produces larger absolute increases in IGF-1 (often 2-3x baseline) compared to GHS (typically 1.3-1.7x baseline), which may explain both the stronger body composition effects and higher side effect burden of HGH
A review of the GHS class found that these compounds increase GH and IGF-1 levels comparable to GH therapy with similar fat loss and lean mass gains but fewer adverse effects (Sigalos and Pastuszak, 2018)
Long-term MK-677 data in older adults showed increased fat-free mass (+1.1 kg) but also raised fasting glucose, demonstrating that GHS are not without metabolic trade-offs

How the mechanisms differ

The fundamental distinction is where each approach acts in the GH axis.

Exogenous HGH is recombinant somatotropin (191 amino acids, 22 kDa) injected subcutaneously. It enters the bloodstream directly, binds GH receptors on target tissues (liver, muscle, fat, bone), and stimulates hepatic IGF-1 production. The injected GH suppresses endogenous GH secretion through negative feedback on the hypothalamus and pituitary. The result is high, sustained GH levels followed by troughs, rather than the natural pattern of 6 to 12 pulsatile GH bursts per day.

GH secretagogues work upstream. They fall into two mechanistic categories:

GHRH analogs (sermorelin, tesamorelin, CJC-1295) bind the GHRH receptor on pituitary somatotropes and stimulate GH synthesis and release. They amplify the natural GH pulse rather than replacing it. Fuh et al. (1998) reviewed the mechanism and noted that GHRH analogs preserve the negative feedback loops that prevent excessive GH levels.^[2]

Ghrelin mimetics (GHRP-2, GHRP-6, ipamorelin, hexarelin, MK-677) bind the growth hormone secretagogue receptor (GHS-R1a, also known as the ghrelin receptor) on pituitary somatotropes. They trigger GH release through a pathway distinct from GHRH, and the two pathways are synergistic: co-administration of a GHRH analog and a ghrelin mimetic produces GH release greater than either alone.^[3]

The pulsatile pattern matters because GH receptor signaling depends on intermittent exposure. Continuous GH exposure (as occurs with high-dose exogenous HGH) leads to GH receptor desensitization, reduced receptor density on target cells, and altered downstream signaling. The pulsatile GH release produced by GHS may achieve biological effects more efficiently per unit of GH, though direct head-to-head comparison data in humans is limited.

Body composition data: what each approach achieves

Exogenous HGH

The landmark body composition data for exogenous HGH comes from studies in GH-deficient adults and aging populations. In adults with confirmed GH deficiency, HGH replacement at physiological doses (0.2-0.6 mg/day) consistently reduces body fat by 4-6 kg and increases lean mass by 2-5 kg over 6 to 12 months. The effects on visceral fat are particularly pronounced, with reductions of 15-30% in CT-measured visceral adipose tissue.

In non-GH-deficient adults, the effects are smaller and the risk-benefit calculation shifts. A meta-analysis of HGH use in healthy older adults found lean mass increases of approximately 2 kg and fat mass decreases of approximately 2 kg, but with significant side effects including edema (41%), arthralgias (30%), carpal tunnel syndrome (24%), and impaired glucose tolerance.

The dose-response relationship is steep. Low-dose HGH (targeting IGF-1 in the normal range) produces modest body composition changes with manageable side effects. Supraphysiological doses (as used in bodybuilding contexts) produce larger body composition effects but dramatically increase the incidence of insulin resistance, fluid retention, and joint pain.

MK-677 (ibutamoren)

MK-677 is the most extensively studied GH secretagogue for body composition because it is orally active, which simplified trial design.

Svensson et al. (1998) conducted a two-month randomized, double-blind, placebo-controlled trial in 24 obese men. MK-677 (25 mg/day) increased 24-hour GH secretion 1.8-fold, raised IGF-1 by 40%, and increased fat-free mass by approximately 3 kg compared to placebo. Serum cortisol also increased transiently.^[4]

Murphy et al. (1998) tested MK-677 in a caloric restriction model and found it reversed diet-induced nitrogen wasting, preserving lean mass during energy deficit. Fat-free mass increased 0.6 kg versus a 2.8 kg loss in the placebo group.^[5]

Longer-term data tempered the initial enthusiasm. A one-year study in healthy older adults found MK-677 increased fat-free mass by 1.1 kg but also increased fat mass and fasting glucose. The net body composition effect was not straightforward fat-to-muscle conversion but rather an increase in both compartments, with the lean mass gain outpacing but not eliminating the fat gain.

GHRP-2

Mericq et al. (2003) examined long-term oral GHRP-2 administration in GH-deficient children and found sustained increases in GH secretion, growth velocity, and changes in body composition favoring lean mass.^[6] The effect was modest compared to full GH replacement, consistent with the lower absolute GH levels achieved through secretagogue stimulation versus exogenous administration.

Ipamorelin

Raun et al. (1998) established ipamorelin as the first selective GH secretagogue. Unlike GHRP-2 and GHRP-6, ipamorelin stimulated GH release without simultaneously increasing ACTH, cortisol, or prolactin. The selectivity was comparable to that of GHRH itself, but acting through the ghrelin receptor pathway.^[7] Body composition data specific to ipamorelin in humans is limited compared to MK-677, but the GH elevations observed suggest comparable potential for lean mass preservation.

Tesamorelin

Tesamorelin is the only GH-related peptide FDA-approved specifically for body composition. It is a GHRH analog approved for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Badran et al. (2026) reviewed body composition, hepatic fat, and metabolic outcomes and confirmed sustained visceral fat reduction with tesamorelin in this population.^[8] For more on tesamorelin specifically, see our article on tesamorelin: the FDA-approved GHRH analog.

Side effect profiles compared

The side effect differences between HGH and GHS are arguably more important than the efficacy differences for most clinical scenarios.

Exogenous HGH carries a well-documented side effect burden at supraphysiological doses: fluid retention and edema, arthralgias and myalgias, carpal tunnel syndrome, insulin resistance and hyperglycemia, gynecomastia, and theoretical concerns about cancer risk (GH and IGF-1 are growth factors). At replacement doses in GH-deficient patients, most of these effects are manageable.

GH secretagogues generally produce fewer side effects because they cannot push GH levels as high as exogenous administration. The pituitary has a finite secretory capacity; GHS amplify what the pituitary can produce rather than bypassing it entirely. Sigalos and Pastuszak (2018) reviewed the GHS class and concluded that these compounds "appear to possess many of the same beneficial effects as those seen with GH therapy itself while demonstrating none of the same adverse side effects or regulatory concerns."^[1]

However, GHS have their own side effect profile:

Appetite stimulation is significant with GHRP-6 and MK-677 due to ghrelin receptor activation. This can be counterproductive for fat loss goals. Ipamorelin and sermorelin produce less appetite stimulation.
Cortisol elevation occurs with GHRP-2 and GHRP-6 (but not ipamorelin or sermorelin), which can promote visceral fat deposition, the opposite of the intended effect.
Prolactin elevation occurs with GHRP-2 and hexarelin at higher doses, potentially affecting sexual function and mood.
Insulin resistance occurs with MK-677 in longer-term studies, similar to exogenous HGH but at lower magnitude.
Water retention occurs with MK-677, though typically less severe than with exogenous HGH.

Smith (2004) reviewed the prospects and pitfalls of the GHS class and noted that the appetite-stimulating effects of ghrelin pathway activators create a paradox: compounds designed to reduce body fat may simultaneously increase caloric intake.^[3]

The pulsatility question

The argument that GHS are superior to HGH because they preserve pulsatile GH secretion is frequently made in clinical peptide circles. The physiological rationale is sound: natural GH secretion occurs in pulses, and GH receptor biology depends on intermittent exposure for optimal signaling. But the clinical significance of this difference for body composition outcomes has not been definitively established in head-to-head trials.

What the available data suggests:

GHS produce GH levels that peak and trough, similar to natural physiology. Exogenous HGH produces a pharmacokinetic profile with a peak 2-6 hours post-injection followed by a gradual decline, which is less physiological than natural pulsatility but not continuous.
The pulsatility of GHS-stimulated GH release is subject to tachyphylaxis (reduced response with repeated dosing). GHRP-6 and hexarelin show attenuated GH responses after several weeks of continuous use. Ipamorelin and sermorelin appear more resistant to tachyphylaxis.
The body composition outcomes achieved by MK-677 (the best-studied GHS for this endpoint) are generally smaller in magnitude than those achieved by HGH at replacement doses, which is consistent with lower absolute GH and IGF-1 levels rather than a pulsatility advantage.

The honest assessment is that GHS produce smaller but cleaner body composition effects compared to exogenous HGH: less lean mass gain and less fat loss, but also less fluid retention, less insulin resistance, and fewer joint symptoms. The trade-off is between magnitude and tolerability.

Who might benefit from each approach

The clinical context determines which approach makes more sense.

Exogenous HGH is established for:

Confirmed adult GH deficiency (diagnosed by stimulation testing)
Pediatric GH deficiency and short stature
HIV-associated wasting
Turner syndrome, Prader-Willi syndrome, and other specific conditions with FDA-approved indications

GH secretagogues may be more appropriate for:

Age-related decline in GH secretion where the pituitary is still functional
Patients who want to amplify endogenous GH without supraphysiological exposure
Patients intolerant of HGH side effects (edema, joint pain)
Settings where preserving hypothalamic-pituitary feedback is desired

Neither approach is established for:

Anti-aging in healthy adults (no RCT evidence of longevity benefit)
Athletic performance enhancement (prohibited by WADA)
Weight loss in the absence of GH deficiency (not FDA-indicated)

The regulatory landscape adds another dimension. Exogenous HGH is FDA-approved for specific indications and tightly controlled. Most GH secretagogues have been placed on the FDA Category 2 list (GHRP-2, GHRP-6, ipamorelin, MK-677), restricting compounding pharmacy access. Sermorelin remains on Category 1. Tesamorelin is FDA-approved for HIV lipodystrophy. For the regulatory details, see FDA Category 1 vs Category 2 Peptides.

What the evidence does not show

Several claims commonly made about GHS vs HGH are not supported by the available clinical data.

No head-to-head RCT has directly compared any GH secretagogue to exogenous HGH for body composition endpoints in the same patient population. All comparisons are cross-study inferences, which are inherently unreliable due to differences in patient selection, dosing, measurement methods, and study duration.

Long-term body composition data for GHS is sparse. The MK-677 data extends to one year. Most GHRP and ipamorelin studies are 4-12 weeks. Whether the body composition effects are durable beyond the initial months of treatment, or whether tachyphylaxis erodes the benefit over time, is unknown.

The muscle-building claims exceed the evidence. GHS increase lean mass by 1-3 kg, which includes water, glycogen, and connective tissue in addition to contractile muscle protein. Whether GH peptides actually build functional muscle in the way that resistance training or anabolic steroids do is a separate and less favorable evidence base.

Selective fat loss is not demonstrated. MK-677 increased both fat-free mass and fat mass in the one-year study. The idea that GHS can selectively burn fat while building muscle is overstated. The more accurate framing is that GHS shift the ratio of fat to lean mass modestly in favor of lean tissue, especially during caloric restriction.

The Bottom Line

GH secretagogues and exogenous HGH both improve body composition by increasing lean mass and reducing fat mass, but through different mechanisms with different trade-offs. HGH delivers larger absolute effects on body composition but carries a higher side effect burden including edema, joint pain, and insulin resistance. GHS produce smaller but cleaner effects by amplifying endogenous pulsatile GH secretion, with ipamorelin showing the most selective profile. No head-to-head clinical trial has directly compared the two approaches, and long-term body composition data for GHS remains limited. The choice between them depends on the clinical context, the patient's GH status, and tolerance for side effects.

Frequently Asked Questions

GH secretagogues produce smaller body composition changes than exogenous HGH at replacement doses. MK-677 increased fat-free mass by approximately 3 kg over two months, comparable to but generally less than what HGH achieves over similar timeframes. The lower efficacy reflects lower absolute GH and IGF-1 levels achieved through pituitary stimulation versus direct hormone administration. The advantage of GHS is fewer side effects, not greater efficacy.

MK-677 increases fat-free mass by 1-3 kg in clinical studies, which includes water and glycogen in addition to contractile muscle. In obese men, a two-month trial showed a 3 kg fat-free mass increase versus placebo. During caloric restriction, MK-677 preserved lean mass that would otherwise be lost. These effects are real but smaller than what exogenous HGH achieves, and the term "fat-free mass" overstates the actual muscle protein gain.

Ipamorelin has the cleanest side effect profile among GH secretagogues. It is the only ghrelin mimetic that stimulates GH release without simultaneously increasing ACTH, cortisol, or prolactin. Sermorelin (a GHRH analog) also has a favorable profile since it works through the natural GHRH pathway. GHRP-2 and GHRP-6 increase cortisol and prolactin, and MK-677 stimulates appetite and can raise fasting glucose.

No. GH secretagogues stimulate the pituitary to release its own GH, preserving the natural hypothalamic-pituitary feedback loops. This is a key difference from exogenous HGH, which suppresses endogenous GH production through negative feedback. When GHS are discontinued, endogenous GH production returns to baseline. With exogenous HGH, there may be a temporary suppression of natural GH secretion after discontinuation.

Neither sermorelin nor HGH has demonstrated anti-aging benefits in randomized controlled trials of healthy adults. Sermorelin stimulates endogenous GH release with fewer side effects than exogenous HGH, and it remains available through compounding pharmacies (Category 1 status). HGH produces larger changes in lean mass and fat mass but with more side effects. The "anti-aging" framing for either therapy is not supported by evidence of increased longevity or healthspan.